Kalaris Therapeutics, Inc.

Aug 11, 2026

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

Kalaris has reported its financial results for Q2 2026, highlighting ongoing patient dosing in the Phase 1b/2 study of TH103. The company anticipates preliminary data in the first half of 2027 and is on track to initiate Phase 3 clinical trials by the end of 2027. As of June 30, 2026, Kalaris holds $93.5 million in cash and equivalents to support its operations.

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

Kalaris has appointed Liisa Bayko as its new Chief Financial Officer, enhancing its leadership team. With over 20 years of experience in biotechnology, Bayko's addition is expected to support the company's growth. Kalaris is currently enrolling patients in its Phase 1b/2 study of TH103 for treatment-naïve nAMD patients.

Jul 17, 2026

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Kalaris Therapeutics has reported encouraging results from the expanded cohorts of its Phase 1a SAD trial for TH103, showing positive outcomes in BCVA, OCT, and pharmacokinetics. The findings support the efficacy observed in earlier cohorts. The company continues to enroll participants in the Phase 1b/2 multiple-ascending dose trial, with preliminary data expected in the first half of 2027.

Jul 6, 2026

Kalaris Appoints Laurie Keating to Board of Directors

Kalaris Therapeutics has appointed Laurie Keating to its Board of Directors. Keating is a highly experienced biotechnology executive, and her expertise is expected to support Kalaris in its upcoming growth phase. This strategic move reflects Kalaris's commitment to advancing its clinical-stage biopharmaceutical initiatives.

Jun 23, 2026

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics has announced an upcoming presentation of its Phase 1a clinical data at the American Society of Retina Specialists. The company is also actively enrolling participants in its Phase 1b/2 clinical trial. This highlights Kalaris's commitment to developing treatments for retinal diseases.

May 12, 2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming do

Kalaris Therapeutics, Inc. reported its financial results for the first quarter of 2026 and provided business updates. The company is currently screening patients in its Phase 1b/2 study for the drug TH103, aimed at treating neovascular Age-related Macular Degeneration, with preliminary data expected in the first half of 2027. Kalaris has $104.9 million in cash reserves, projected to fund operations through late 2027, while planned Phase 3 trials are slated for initiation by year-end 2027. However, a continued net loss and rising operational costs were noted in the financial report.

Mar 17, 2026

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 s

Kalaris Therapeutics reported positive initial data from its Phase 1a trial for TH103, aimed at treating neovascular age-related macular degeneration (nAMD), and announced financial results for 2025. The company completed a $50 million private placement and expects its cash reserves will fund operations into the fourth quarter of 2027. While research and development expenses decreased, general administrative expenses rose sharply. Additionally, the net loss for the year was significantly lower than the previous year.

Mar 9, 2026

Forward-Looking Statements & Disclaimer This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange A

Kalaris has provided insights into its forward-looking plans related to its lead drug candidate TH103, intended for retinal diseases. The company has outlined a timeline for clinical trials, however, it warns of various risks and uncertainties inherent to the development process. Additionally, Kalaris indicated it has sufficient cash resources to fund operations into late 2027, following a successful private placement. The drug TH103, which has shown initial promise, aims to address significant unmet medical needs in the market for retinal treatments.

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics has announced an oversubscribed private placement that will raise approximately $50 million. The offering, involving both new and existing institutional investors, is set to close soon and will be used to advance the clinical development of TH103 for neovascular AMD, alongside other corporate purposes. The securities will not be registered under the Securities Act, necessitating a registration rights agreement with the investors.

Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in Treatment-Na ve Neovascular AMD TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a si

Kalaris Therapeutics reported promising initial data from its Phase 1a study of TH103, indicating significant improvements in visual acuity and retinal anatomy in treatment-naive neovascular AMD patients. The treatment showed a mean gain of 10 letters in visual acuity at Month 1 and was generally well tolerated, prompting plans for further dose escalation. Moreover, a notable pharmacokinetic profile suggested enhanced intraocular retention, which may lead to extended treatment durability. Expected preliminary data from the ongoing Phase 1b/2 study is anticipated in the second half of 2026.

Nov 12, 2025

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reported by year end 2025 Phase 1b/2 Multiple Ascen

Kalaris Therapeutics reported its financial results for Q3 2025, highlighting significant corporate milestones and progress in clinical trials. The Phase 1a Single Ascending Dose trial remains on schedule for initial data by year's end, while the Phase 1b/2 trial is currently enrolling participants. The company has substantial cash reserves of $77 million, projected to fund operations into 2027 even as R&D expenses reflect past obligations. Despite a notable net loss, the company is advancing its investigational treatment TH103 aimed at retinal diseases.

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provid

Kalaris Therapeutics reported its financial results for Q2 2025, highlighting a net loss of $11.4 million, a significant increase from the previous year. The company continues to enroll patients in a Phase 1 trial for its new anti-VEGF agent, TH103, with initial data expected by Q4 2025. Kalaris currently holds $88.4 million in cash, which is projected to sustain operations through Q4 2026. The upward trend in R&D and administrative expenses indicates growing operational complexities as the company advances its clinical programs.

May 14, 2025

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provid

Kalaris Therapeutics has reported its financial results for the first quarter of 2025, highlighting a cash position of $101 million due to the merger with AlloVir. The company is actively enrolling patients for its Phase 1 trial of TH103, an anti-VEGF therapy aimed at treating neovascular age-related macular degeneration. Despite a reported net loss of $10.2 million, the company expresses optimism about the clinical potential of TH103 and anticipates initial trial data in Q4 2025.

Mar 19, 2025

Kalaris Announces Closing of Merger with AlloVir Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat

Kalaris Therapeutics, Inc. has successfully completed its merger with AlloVir, enhancing its capabilities to develop TH103, an innovative anti-VEGF agent. TH103 aims to address treatment limitations for neovascular diseases of the retina, currently undergoing a Phase 1 trial with initial data projected for late 2025. The merger provides Kalaris with approximately $100 million in cash to sustain its operations well into 2026. As it transitions onto the Nasdaq Global Market under ticker KLRS, the company is poised for continued growth in the biopharmaceutical space.

Mar 12, 2025

Kalaris and AlloVir Announce Stockholder Approval of Merger Combined company expected to trade on Nasdaq under KLRS after closing PALO ALTO, Calif. and

Kalaris and AlloVir have announced that AlloVir stockholders approved the proposed merger during a special meeting. The merger, which is expected to close soon, will result in the new entity operating under the Kalaris name and trading on Nasdaq with the ticker KLRS. Kalaris, a clinical-stage biopharmaceutical company, is focused on developing treatments for retinal diseases, notably its investigational therapy TH103. However, the completion of the merger faces various market and operational uncertainties.

Nov 8, 2024

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and

AlloVir Inc. has entered into a definitive merger agreement with Kalaris Therapeutics to create a combined entity focused on retinal diseases. The merger will involve AlloVir acquiring Kalaris, leading to a company that will operate under the Kalaris name and trade under the ticker KLRS. The new entity aims to accelerate the clinical development of TH103, a novel anti-VEGF therapy for conditions such as neovascular age-related macular degeneration. With an anticipated cash balance of approximately $100 million post-merger, the combination is projected to fund operations into Q4 2026. Initial clinical data for TH103 is expected in Q3 2025.

Nov 7, 2024

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

AlloVir and Kalaris Therapeutics have announced a merger agreement aimed at forming a new company dedicated to addressing diseases of the retina. This strategic move is expected to consolidate their efforts in research and development, potentially leading to innovative solutions in the field. The merger reflects a commitment to advancing treatment options for retinal conditions.

Dec 22, 2023

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSM

AlloVir has announced the discontinuation of its three Phase 3 clinical trials for posoleucel, an allogeneic virus-specific T cell therapy, following recommendations from Data Safety Monitoring Boards that found the studies unlikely to achieve their primary goals. Despite the setback, no safety concerns were identified. The company intends to focus on conserving capital and reviewing strategic alternatives, having reported $213.3 million in available cash and investments as of September 30, 2023. AlloVir is in discussions with regulatory authorities regarding the outcomes of the trials.

Nov 2, 2023

AlloVir Reports Third Quarter 2023 Financial Results Posoleucel, a highly innovative off-the-shelf, multi-virus-specific investigational T cell therapy, continues to advance in three distinct, Phase 3, first-to-market in

AlloVir announced its financial results for the third quarter of 2023, highlighting significant advancements in its lead therapy, posoleucel, which is in Phase 3 trials for multiple viral infections in immunocompromised patients. The company reported financial resources of $213.3 million, ensuring support through upcoming trial milestones expected in late 2024. While demonstrating a strong pipeline, AlloVir is facing challenges with ongoing operational losses and the necessity to meet regulatory expectations for its product development.

Aug 3, 2023

AlloVir Reports Second Quarter 2023 Financial Results Company s three Phase 3 global registrational trials for its allogeneic, off-the-shelf, virus-specific T cell therapy, posoleucel, in three distinct, first-to-market

AlloVir reported its financial results for Q2 2023, highlighting progress in its three Phase 3 global trials of posoleucel, an off-the-shelf T cell therapy. The trials are aimed at allo-HCT patients and are expected to conclude enrollment with data anticipated in the second half of 2024. A recent stock offering has extended the company's cash runway through 2025, allowing it to fund operations while awaiting clinical data for posoleucel. Additionally, positive Phase 2 results for posoleucel treating BK viremia were shared, indicating potential efficacy in immunocompromised patients.

Jun 21, 2023

AlloVir Announces Proposed Public Offering of Common Stock Cambridge, Mass.

AlloVir, Inc. has announced a proposed underwritten public offering of $75 million of its common stock, with an option for underwriters to purchase an additional 15% of the shares. The company plans to use an effective shelf registration statement previously filed with the SEC for this offering. J.P. Morgan, Morgan Stanley, and BofA Securities are managing the offering. While the announcement highlights AlloVir's intent to raise capital for its clinical programs, the completion of the offering is subject to market conditions and other factors.

May 4, 2023

AlloVir Reports First Quarter 2023 Financial Results Company s three posoleucel Phase 3 global registrational trials for three distinct, first-to-market indications continue to enroll with data readouts on track for 2024

AlloVir has reported its financial results for the first quarter of 2023, continuing the enrollment in three Phase 3 global trials for its lead therapy, posoleucel. The company's upcoming data readouts scheduled for 2024 are anticipated to shed light on the therapy's effectiveness against severe viral infections following hematopoietic cell transplants. Additionally, promising Phase 2 trial results for posoleucel in kidney transplant recipients are set to be presented at the American Transplant Congress 2023, signaling potential advancements in treatment options for patients with compromised immune systems.

Feb 23, 2023

AlloVir Appoints Derek Adams, Ph.D., to Board of Directors Waltham, Mass.

AlloVir has appointed Derek Adams, Ph.D., to its Board of Directors effective March 1, 2023. Dr. Adams, who has more than 20 years of experience in the biopharmaceutical industry, will support the company's advancement of its posoleucel Phase 3 studies. His appointment comes as AlloVir prepares for potential regulatory submissions and commercialization. Dr. Adams replaces Ansbert Gadicke, M.D., who has served on the Board since 2018 and has been instrumental in guiding the company's growth.

Feb 15, 2023

AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook Completion of enrollment of all three posoleucel Phase 3 registrational trials for three distinct, first-to-market indications anticipated by end of 2023

AlloVir, Inc. reported its full-year 2022 financial outcomes and outlined its 2023 outlook, indicating the completion of enrollment in three Phase 3 registrational trials for its lead therapy, posoleucel. Results from a Phase 2 study in kidney transplant patients demonstrated positive safety and efficacy outcomes. With a robust cash position and plans for data readouts in 2024, AlloVir is positioned for potential growth. The company is focused on expanding its pipeline and working with regulatory authorities for future clinical development.

Jan 9, 2023

AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023 Positive final posoleucel Phase 2 clinical data presented at ASH 2022 underscore potential as multi-virus p

AlloVir has announced plans to complete enrollment in three Phase 3 registrational trials for its investigational therapy, posoleucel, by the end of 2023. This follows positive data reported from a Phase 2 study demonstrating the therapy's potential to reduce significant viral infections in vulnerable transplant patients. The trials will target the prevention and treatment of infections related to several viruses, indicating the company's focus on addressing unmet medical needs in viral disease management. Topline results from these studies are expected in 2024.

Nov 3, 2022

AlloVir Reports Third Quarter 2022 Financial Results Posoleucel Continues to Advance in Three Ongoing Multi-National Phase 3 Registrational Trials Final Data Presentation from Posoleucel Phase 2 Multi-Virus Prevention St

AlloVir Reports Third Quarter 2022 Financial Results Posoleucel Continues to Advance in Three Ongoing Multi-National Phase 3 Registrational Trials Final Data Presentation from Posoleucel Phase 2 Multi-Virus Prevention Study by Year-End Company to Host Investor Webcast on Decem

Aug 4, 2022

AlloVir Reports Second Quarter 2022 Financial Results Three Phase 3 Posoleucel Registrational Trials Continue to Expand Globally, Enrolling Patients in the U.S., Europe and Asia Company Is On Track to Release Final Resul

AlloVir Reports Second Quarter 2022 Financial Results Three Phase 3 Posoleucel Registrational Trials Continue to Expand Globally, Enrolling Patients in the U.S., Europe and Asia Company Is On Track to Release Final Results of Posoleucel Phase 2 Multi-Virus Prevention Study at

Jul 27, 2022

AlloVir Announces $126.6 Million Registered Direct Offering Proceeds Support the Completion of Three Global Phase 3 Registrational Trials for Posoleucel and Global Regulatory Filings Waltham, Mass.

AlloVir Announces $126.6 Million Registered Direct Offering Proceeds Support the Completion of Three Global Phase 3 Registrational Trials for Posoleucel and Global Regulatory Filings Waltham, Mass., July 27, 2022 AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage allogeneic T

May 5, 2022

AlloVir Reports First Quarter 2022 Financial Results Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S.,

AlloVir Reports First Quarter 2022 Financial Results Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia FDA granted RMAT designation to posoleucel for Phase 3

Mar 31, 2022

AlloVir Appoints Shawn Tomasello to Its Board of Directors Waltham, Mass.

AlloVir Appoints Shawn Tomasello to Its Board of Directors Waltham, Mass., March 31, 2022 AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings mo

Feb 10, 2022

AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no

AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of po

Jan 10, 2022

KLRSConferences/Events

A Leader in Allogeneic, Off-the-Shelf, Virus-Specific T Cell Therapies J.P. Morgan Healthcare Conference

Therapies J.P. Morgan Healthcare Conference January 10, 2022 CONFIDENTIAL & PROPRIETARY 2022 Disclaimer This presentation has been prepared by AlloVir, Inc. ("we," "us," "our," "AlloVir" or the "Company") and is made for informational purposes only and does not constitute an of

Dec 16, 2021

AlloVir Announces Departure of Chief Medical Officer Agustin Melian Waltham, Mass.

AlloVir Announces Departure of Chief Medical Officer Agustin Melian Waltham, Mass. December 16, 2021 - AlloVir (Nasdaq: ALVR) today announced that Agustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially leaving th

Dec 11, 2021

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting Of the 23 high-risk allogeneic

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting Of the 23 high-risk allogeneic hematopoietic cell transplant patients in this analysis, no end-organ viral dise

Nov 15, 2021

KLRSConferences/Events

A Leader in Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies November 2021 CONFIDENTIAL & PROPRIETARY 2021 Disclaimer This presentation has been prepared by AlloVir, Inc. ("we," "us," "our," "AlloVir" or the "C

T-Cell Therapies November 2021 CONFIDENTIAL & PROPRIETARY 2021 Disclaimer This presentation has been prepared by AlloVir, Inc. ("we," "us," "our," "AlloVir" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation

Nov 5, 2021

AlloVir Reports Third Quarter 2021 Financial Results Company is prioritizing prevention and treatment programs with the potential to transform transplant patient care and outcomes Positive interim d

AlloVir Reports Third Quarter 2021 Financial Results Company is prioritizing prevention and treatment programs with the potential to transform transplant patient care and outcomes Positive interim data from posoleucel multi-virus prevention Phase 2 study will be presented at AS

Aug 6, 2021

AlloVir Reports Second Quarter 2021 Financial Results - Posoleucel (Viralym-M, ALVR105) proof-of-concept studies in multi-virus prevention in stem cell transplant patients and BK viremia in kidney transplant patients con

AlloVir Reports Second Quarter 2021 Financial Results - Posoleucel (Viralym-M, ALVR105) proof-of-concept studies in multi-virus prevention in stem cell transplant patients and BK viremia in kidney transplant patients continue to progress with initial data - Posoleucel Phase 3

May 6, 2021

AlloVir Reports First Quarter 2021 Financial Results - Viralym-M pivotal trial in virus-associated hemorrhagic cystitis continues to progress enrollment - Viralym-M proof-of-concept studies in multi-virus prevention in s

AlloVir Reports First Quarter 2021 Financial Results - Viralym-M pivotal trial in virus-associated hemorrhagic cystitis continues to progress - Viralym-M proof-of-concept studies in multi-virus prevention in stem cell transplant and BK viremia in kidney transplant continue to

Mar 22, 2021

AlloVir Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective

AlloVir Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective May 17, 2021 David Hallal to continue as Executive Chairman of the AlloVir Cambridge, MA, March 22, 2021 AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that it

Feb 11, 2021

AlloVir Reports Full Year 2020 Financial Results Initiated Phase 3 pivotal clinical trial with Viralym-M, an off-the-shelf multi-virus-specific investigational T-cell therapy, for the treatment of virus-associated hemorr

AlloVir Reports Full Year 2020 Financial Results Cambridge, MA, February 11, 2021 AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today provided a corporate update and reported full-year 2020 financial results for the period ended December 31, 2020. Since c

Jan 14, 2021

KLRSConferences/Events

Disclaimer This presentation has been prepared by AlloVir, Inc. ("we," "us," "our," "AlloVir" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an

A Leader in Allogeneic, Off-the-Shelf Virus-Specific T-Cell Immunotherapies Exhibit 99.1 Disclaimer This presentation has been prepared by AlloVir, Inc. ("we," "us," "our," "AlloVir" or the "Company") and is made for informational purposes only and does not constitute an offer

Dec 17, 2020

KLRSFDA Updates

AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses Proof-of-concept phase

AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses Proof-of-concept phase 1/2 trial to initiate in 2021 to treat severe respirato

Dec 7, 2020

Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62 nd American Society of Hematology Annual Meeting - Viralym-M, an allogeneic, off-the-shelf, multi-

Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual Meeting Viralym-M, an allogeneic, off-the-shelf, multi-virus specific T-cell therapy demonstrates 93% of patients achieved a clinical

Dec 5, 2020

Preclinical Data Demonstrate Anti-Viral Activity of AlloVir s ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy - Data presented in an oral presentation at the 62 nd American Society of Hematology

Preclinical Data Demonstrate Anti-Viral Activity of AlloVir s ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy - Data presented in an oral presentation at the 62nd American Society of Hematology Annual Meeting clinical trial underway for high-risk patie

Nov 10, 2020

AlloVir Reports Third Quarter 2020 Financial Results Completed initial public offering raising $317.7M in gross proceeds Viralym-M (multi-virus-specific T cell therapy) registrational study in lead indication in virus-as

AlloVir Reports Third Quarter 2020 Financial Results Completed initial public offering raising $317.7M in gross proceeds Viralym-M (multi-virus-specific T cell therapy) registrational study in lead indication in virus-associated hemorrhagic cystitis and proof-of-concept study

Sep 17, 2020

KLRSFDA Updates

AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients - ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candi

AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients - ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to for high-risk COVID-19 patients - Proo

Sep 2, 2020